More recently, an in vivo study evaluated a peptide capable of restoring the localization and upregulation of ADAM10 activity at the early stages of the disease, hence rescuing cognitive defects, further supporting the therapeutic potential of ADAM10 in AD (Musardo et al., 2022). The gene discussed is ADAM10; the disease is Cognitive impairment.